KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Net Margin (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Net Margin for 13 consecutive years, with 9.71% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 970.0% year-over-year to 9.71%, compared with a TTM value of 5.04% through Dec 2025, up 543.0%, and an annual FY2025 reading of 5.04%, up 543.0% over the prior year.
  • Net Margin was 9.71% for Q4 2025 at Travere Therapeutics, up from 0.01% in the prior quarter.
  • Across five years, Net Margin topped out at 646.92% in Q3 2023 and bottomed at 113.63% in Q1 2021.
  • Average Net Margin over 5 years is 42.96%, with a median of 9.71% recorded in 2025.
  • The sharpest move saw Net Margin skyrocketed 59561bps in 2023, then tumbled -64702bps in 2024.
  • Year by year, Net Margin stood at 56.1% in 2021, then rose by 20bps to 67.53% in 2022, then tumbled by -105bps to 3.5% in 2023, then skyrocketed by 100bps to 0.01% in 2024, then surged by 181434bps to 9.71% in 2025.
  • Business Quant data shows Net Margin for TVTX at 9.71% in Q4 2025, 0.01% in Q4 2024, and 0.09% in Q3 2024.